The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication
Earlier studies demonstrated that the incretin effect of GIP was severely impaired in patients with uncontrolled T2DM ( In contrast, while the dose-response relationship between -cell responsiveness to glucose (expressed as the slope of the linear relation between insulin secretion rate and the glucose concentration) and GLP-1 levels in circulation is partially impaired a phenomenon referred as GLP-1 resistance ( Furthermore, a preclinical study conducted by Finan et al
The drug also reduced liver fat by an average of 53% in the 2.4 mg cohort
Nat Rev Nephrol 13:605 Skov J (2014) Effects of GLP-1 in the Kidney
arms) Retest every 68 weeks We Can Help You Stay Strong While You Slim Down At Central Ohio Spine and Joint, we specialize in helping people: Preserve or rebuild muscle mass Manage pain and movement dysfunction Rehabilitate after injury or surgery Train smarter as they age If youre on a GLP-1 and want to avoid muscle lossor youre already feeling weaker and more injury-pronewe can help with: Strength training programs tailored to weight loss Injury prevention screenings using Kinetisense and grip strength Recovery strategies that support both fat loss and lean mass retention Losing weight shouldnt mean losing your strength
